Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers
This study is ongoing, but not recruiting participants.
First Received: March 8, 2007   Last Updated: August 3, 2009   History of Changes
Sponsors and Collaborators: Southern California Institute for Research and Education
Heritage Medical Research Institute
Information provided by: Southern California Institute for Research and Education
ClinicalTrials.gov Identifier: NCT00446472
  Purpose

The objective of this study is to compare the effectiveness and safety of windowed casts with Regranex® (topical becaplermin gel) versus placebo (inactive medication) for treatment of diabetic ulcers on the legs and feet.


Condition Intervention
Diabetic Foot Ulcers
Drug: Regranex®
Drug: Hydrogel

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Evaluation of Windowed Casts With and Without Regranex® Gel for Healing

Resource links provided by NLM:


Further study details as provided by Southern California Institute for Research and Education:

Primary Outcome Measures:
  • Completely healed wounds [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: April 2007
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Randomized to Regranex gel
Drug: Regranex®
Regranex gel will be used for a total of 16 weeks
2: Active Comparator
Placebo hydrogel will be used for a total of 16 weeks
Drug: Hydrogel
Placebo hydrogel will be applied for 16 weeks

Detailed Description:

Management of diabetic leg or foot ulcers is based on certain principals: 1) effective off-loading of pressure on the wound via specialized shoes, cast braces, or casts, 2) removal of infected or necrotic tissue vial surgery or non-surgical methods, and 3) optimization of wound healing by interventions that promote wound repair such as nutritional support, provision of optimal moisture balance and growth factor therapy.

Application of casts or cast braces [below knee, removable boots with protective padding] to protect and immobilize the ankle and foot have been demonstrated to provide superior wound healing than less cumbersome types of shoe gear (1-3). The benefit of casting may be the result of more effective off-loading of pressure than can be achieved with other devices, but the inability of patients to remove their casts also appears to an important factor, as non-compliance with removable cast-braces has been shown to be a pervasive and significant issue (4,5). One critical concept in diabetic foot ulcer management is the relation between chronically and limb loss — for each year a wound persists, a patient has a 25% risk for major amputation due to complications from infection (6-8). Limb loss has a profound effect on Diabetics' quality of life and rate of lower limb loss among diabetics is four per 1,000 person years in comparison with three per 10,000 person years (9-10).

  Eligibility

Ages Eligible for Study:   21 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must sign an informed consent
  • Have a history of compliance and reliability in following study required treatment regimen.
  • Have diabetic mellitus Type I or Type II and have a glycohemoglobin Alc less than l0
  • Presence of one or two ulcers in lower extremities

    1. Wounds cannot be positioned more than 2.5cm proximal to the malleoli, but may involve any more distal position of the foot
    2. Type 2 Diabetic Mellitus Neuropathic ulcers present at least for 3months with failure to heal
    3. Post-operation wounds in DM patients with wound present for minimum 4 weeks after surgery and wound surface area has failed to decrease more than 20% in 4 weeks
    4. Ulcer(s) must be stage II or III full-thickness (extending through the subcutaneous tissue or beyond - Wagner grade II or III)
    5. No joint, tendon or bone exposure
    6. Located on the lower extremity.
    7. Ulcer size measures 1cm2 < 16 cm2
    8. No osteomyelitis affecting the area of the ulcer
    9. If two wounds, both can be incorporated into one window when cast applied
  • Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.

Exclusion criteria:

  • Female subjects who are within child bearing age range.
  • Previous sensitivity to Regranex® Gel.
  • Use of topical antibiotics, enzymatic debriders on the selected ulcer(s) within 30 days preceding randomization.
  • Osteomyelitis affecting the area of the selected ulcer(s)
  • Exposed bone, joint or tendon at ulcer site (Wagner III or higher)
  • Presence of more than two full-thickness ulcers on targeted lower extremity
  • Requirement for systemic antibiotics use within 7 days of study entry
  • Inability to tolerate cast
  • Presence of systemic or local cancer of any kind
  • Life expectancy less than 1 year
  • Subjects with end stage renal failure requiring chronic hemodialysis
  • Concomitant use of Pletal or other vasodilators
  • Ankle Brachial Index less or equal to 0.8 or toe pressure index less than 0.6
  • ESR>20
  • Demonstration of poor compliance including a chronic alcohol, psychiatric condition or drug abuse problems
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00446472

Locations
United States, California
VA Long Beach Healthcare System
Long Beach, California, United States, 90822
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073
Sponsors and Collaborators
Southern California Institute for Research and Education
Heritage Medical Research Institute
Investigators
Principal Investigator: Ian Gordon, M.D., Ph.D. VA Long Beach Healthcare System
Principal Investigator: Aksone Nouvong, D.P.M. VA Greater Los Angeles Healthcare System
  More Information

Additional Information:
Publications:
Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001 Jun;24(6):1019-22. Erratum in: Diabetes Care 2001 Aug;24(8):1509.
Ha Van G, Siney H, Hartmann-Heurtier A, Jacqueminet S, Greau F, Grimaldi A. Nonremovable, windowed, fiberglass cast boot in the treatment of diabetic plantar ulcers: efficacy, safety, and compliance. Diabetes Care. 2003 Oct;26(10):2848-52.
Caravaggi C, Faglia E, De Giglio R, Mantero M, Quarantiello A, Sommariva E, Gino M, Pritelli C, Morabito A. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. Diabetes Care. 2000 Dec;23(12):1746-51.
Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003 Sep;26(9):2595-7.
Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care. 2005 Mar;28(3):551-4.
Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabet Med. 1995 Sep;12(9):770-6.
Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes. 1991 Oct;40(10):1305-13.
Bergink GJ, Hoyng CB, van der Maazen RW, Vingerling JR, van Daal WA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):321-5.
Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990 May;13(5):513-21.

Responsible Party: VA Long Beach Health Care System ( Ian Gordon, M.D. )
Study ID Numbers: #778
Study First Received: March 8, 2007
Last Updated: August 3, 2009
ClinicalTrials.gov Identifier: NCT00446472     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Southern California Institute for Research and Education:
diabetes mellitus
diabetic neuropathies
peripheral vascular diseases

Study placed in the following topic categories:
Foot Ulcer
Peripheral Vascular Diseases
Diabetic Neuropathies
Skin Diseases
Ulcer
Vascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Foot Diseases
Diabetic Angiopathies
Platelet-derived growth factor BB
Mitogens
Angiogenesis Inducing Agents
Endocrinopathy
Skin Ulcer
Diabetes Complications
Diabetic Foot
Leg Ulcer

Additional relevant MeSH terms:
Foot Ulcer
Diabetic Neuropathies
Skin Diseases
Growth Substances
Ulcer
Physiological Effects of Drugs
Vascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Foot Diseases
Pharmacologic Actions
Diabetic Angiopathies
Pathologic Processes
Platelet-derived growth factor BB
Angiogenesis Inducing Agents
Cardiovascular Diseases
Angiogenesis Modulating Agents
Skin Ulcer
Diabetes Complications
Diabetic Foot
Leg Ulcer

ClinicalTrials.gov processed this record on August 28, 2009